Tc-99m-annexin V-128

Drug Profile

Tc-99m-annexin V-128

Alternative Names: 99mTc-rhAnnexin V-128; 99mTechnetium-labelled rhAnnexin V-128; rhAnnexin V-128; Tc-99m-recombinant human annexin V-128; Tc-99m-rhAnnexin V-128

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Atreus Pharmaceuticals
  • Developer Advanced Accelerator Applications; INSERM
  • Class Calcium binding proteins; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cardiomyopathies; Carotid stenosis; Spondylarthritis
  • Phase I/II Ankylosing spondylitis; Cardiovascular disorders; Rheumatoid arthritis
  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 26 Oct 2017 Atreus Pharmaceuticals terminates a phase I/II trial in Ankylosing spondylitis and Rheumatoid arthritis (Diagnosis) in Switzerland due to low recruitment (IV) (NCT02328027)
  • 18 Sep 2017 Phase-II clinical trials in Spondylarthritis (Diagnosis) in USA (IV) (NCT03232580)
  • 01 Aug 2017 Advanced Accelerator Applications plans a phase II trial for Spondylarthritis (Diagnosis) (IV) (NCT03232580)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top